Boehringer Ingelheim GmbH
Corporate Division Public Relations
Judith von Gordon
Binger Strasse 173
55216 Ingelheim am Rhein
Ingelheim/Germany, 30 June 2005 - Boehringer Ingelheim announced today to publish with in the next weeks their clinical trials online. All confirmatory trials initiated on or after July 1, 2005 will be made public by posting information prior to start of patient enrolment in a trial repository maintained by the National Library of Medicine in the U.S.
“In line with an announcement of the International Federation of Pharmaceutical Manufacturers Associations earlier this year, Boehringer Ingelheim is committed to offer as much transparency as possible on our clinical trials to doctors, nurses, pharmacists, patients and all other interested parties. At one central location everybody will be able to access key information on confirmatory clinical trials, including medical conditions being studied, number of patients and centres, as well as trial timelines. We are sure that this approach offers health care personnel and patients the possibility to find out more about the drug they started to use or drugs that are yet to be marketed,” said Dr. Andreas Barner, member of the Board of Managing Directors of Boehringer Ingelheim and responsible for Research, Development and Medicine.
In addition to posting all clinically directive phase II-IV clinical trials at “www.clinicaltrials.gov”, Boehringer Ingelheim will publish the results of these trials on a company web page for products commercially available in at least one country.
For products developed or marketed under collaboration with other companies, Boehringer Ingelheim agreed with its partners that the license holder will be responsible for providing information. All trials initiated on or after 1st July, 2005 will be submitted to the registry. In addition, all ongoing clinical trials will be posted not later than 13th September, 2005.
Results of completed trials will be made available on the Boehringer Ingelheim web page after the drug is first approved and marketed in any country within one year after trial completion. In addition once the IFPMA portal has been launched Boehringer Ingelheim’s clinical trial information for both ongoing and completed trials will also be assessable via the IFPMA portal.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2004, Boehringer Ingelheim posted net sales of 8.2 billion euro while spending nearly one fifth of net sales in its largest business segment Prescription Medicines on research and development.